Table A. Characteristics of the unmatched COVID-19 cohort and the matched COVID-19 and influenza cohorts. Table B. Contributions of incidence (within 6 months of a diagnosis of COVID-19 vs. influenza) of subcategories making up the clinical features of long-COVID in matched cohorts. Table C. Incidence of long-COVID features in the whole cohort of patients with COVID-19 within the entire follow-up period (0–6 months), the first half of the follow-up period (0–3 months), and the second half of the follow-up period (3–6 months). In the analysis of the 3–6-month follow-up, those who had the long-COVID feature recorded in the first 3 months and then again in the next 3 months were included so that the sum of the incidences in the two-halves of the follow-up window exceeds the total incidence. Table D. Absolute risk increase in COVID-19 vs. influenza (a positive number indicates a higher risk in COVID-19) in the whole 0–6-month period as well as the “long” phase (3–6 months). Table E. 95% CIs corresponding to the entries in Fig 3A of the main manuscript, i.e., for the incidence (on the diagonal) and co-occurrence (off-diagonal) of long-COVID features in the 6 months after a diagnosis of COVID-19. Table F. 95% CIs corresponding to the entries in Fig 3B of the main manuscript, i.e., for the incidence (on the diagonal) and co-occurrence (off-diagonal) of long-COVID features in the period extending from 3 to 6 months after a diagnosis of COVID-19. Table G. 95% CIs corresponding to the entries in Fig 3C of the main manuscript, i.e., for the HRs of the incidence (on the diagonal) and co-occurrence (off-diagonal) of long-COVID features in the 6 months after a diagnosis of COVID-19 vs. influenza. All corresponding p-values were p = 0.0007). Table H. 95% CIs corresponding to the entries in Fig 3D of the main manuscript, i.e., for the HRs of the incidence (on the diagonal) and co-occurrence (off-diagonal) of long-COVID features in the period extending from 3 to 6 months after a diagnosis of COVID-19 vs. influenza. All corresponding p-values were p = 0.1476), myalgia and cognitive symptoms (p = 0.1292), and myalgia and pain (p = 0.0139). Table I. p-values for the test of proportional hazards (obtained using the generalized Schoenfeld test) for the main analysis (1 day to 6 months follow-up) and the analysis restricted to the 3 months–6 months follow-up. A value lower than 0.05 indicates evidence for nonproportional hazards. Table J. Average degrees of the clinical feature networks in the different comparisons between cohorts. p-values were obtained using permutation tests. Table K. 6-month incidence of individual long-COVID features and of any feature in different subgroups of patients (defined by sex, race, or age) diagnosed with COVID-19. Table L. 6-month incidence of individual long-COVID features and of any feature in different subgroups of patients defined by indices of severity of COVID-19 illness. Table M. Characteristics of the female and male COVID-19 cohorts after propensity score matching. Table N. Characteristics of the non-white and white COVID-19 cohorts after propensity score matching. Table O. Characteristics of the age 45+ and age 10–44 COVID-19 cohorts after propensity score matching. Table P. Characteristics of the age 65+ and age 45–64 COVID-19 cohorts after propensity score matching. Table Q. Characteristics of the age 22–44 and age 10–21 COVID-19 cohorts after propensity score matching. Table R. Characteristics of COVID-19 cohorts requiring and not requiring hospitalization, after propensity score matching. Table S. Characteristics of COVID-19 cohorts requiring and not requiring ITU admission, after propensity score matching. Table T. Characteristics of leukocytosis and non-leukocytosis COVID-19 cohorts after propensity score matching. Table U. Mean count number of occurrences of each and any long-COVID feature among patients who have them recorded at least once, in the 6 months after a diagnosis of COVID-19 or influenza (using matched cohorts). The p-value tests the hypothesis that the counts are equal between the cohorts. Table V. Comparison in the 6-month incidence of any pain, between patients with COVID-19 and a matched cohort of patients with influenza. Any pain in this analysis refers to the composite endpoint of chest/throat pain, headache, myalgia, other pain (as defined in Supporting Methods D) or abdominal and pelvic pain (a subcategory of the abdominal symptoms also defined in Supporting Methods D). CI, confidence interval; COVID-19, Coronavirus Disease 2019; HR, hazard ratio; ITU, intensive treatment unit; SMD, standardized mean difference. (DOCX)</p
